Robert Mittendorff
General Partner at B Capital
Robert Mittendorff
General Partner at B Capital
San Francisco Bay Area
Overview
Work Experience
General Partner and Head of Healthcare
2021 - Current
B Capital Group is a venture capital firm that backs global entrepreneurs in the field of information technology.
Board Member
2024
Nalu Medical is a medical technology company that develops innovative solutions for patients with chronic neuropathic pain.
Raised $200,915,367.00 from Pura Vida Investments, Aperture Venture Partners, Advent Life Sciences, Longitude Capital, B Capital, Decheng Capital, Endeavour Vision, Novo Holdings, Gilde Healthcare and MVM Life Science Partners.
Member Board Of Directors
2022
Capital Rx is a healthtech platform that provides pharmacy benefit management solutions.
Raised $252,960,628.00 from Prime Therapeutics.
Board Member
2023
Member Board Of Directors
2022
The company manufactures and sells the aprevo™ digital-to-device 3-D printed implant system for lumbar spine surgery.
Raised $96,985,000.00 from U.S. Venture Partners and B Capital.
Member Board Of Directors
2021
Lively is a modern Health Savings Account (HSA) platform for employers and individuals.
Raised $122,200,000.00 from B Capital, Costanoa Ventures and Titanium Ventures.
Member Board of Directors
2021
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Raised $210,000,000.00 from Pavilion Capital, Revelation Partners, SR One, LSP BioVentures, Monashee Investment Management, B Capital, Atlas Venture, Sofinnova Partners, CaaS Capital Management and Pivotal bioVenture Partners.
Board Member
2022
Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.
Raised $100,000,000.00 from Myeloma Investment Fund, Multiple Myeloma Research Foundation, Northpond Ventures, Leaps by Bayer, B Capital, ATEM Capital Fund LP, Northpond Ventures, Bloom Burton & Co., Centre for Commercialization of Cancer Immunotherapy and Leaps by Bayer.
Board Observer
2024
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.
Raised $119,000,000.00 from Polaris Partners, Cornell University, Droia Ventures, Eli Lilly, Catalio Capital Management, ARCH Venture Partners, Vida Ventures and Meyer Ventures.
Board Observer
2021
Aetion provides real-world evidence (RWE) and outcomes-based analytics solutions to life science companies and payers.
Raised $203,600,000.00 from B Capital, Warburg Pincus, Foresite Capital, Flare Capital Partners and New Enterprise Associates.
Education
B.S. (high honors)
1994 - 1998